Longeveron Inc. (NASDAQ:LGVN) Sees Large Decrease in Short Interest

Longeveron Inc. (NASDAQ:LGVN) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 979,704 shares, a decrease of 26.6% from the December 15th total of 1,334,145 shares. Based on an average daily trading volume, of 372,571 shares, the short-interest ratio is presently 2.6 days. Currently, 5.2% of the company’s stock are sold short. Currently, 5.2% of the company’s stock are sold short. Based on an average daily trading volume, of 372,571 shares, the short-interest ratio is presently 2.6 days.

Longeveron Price Performance

NASDAQ LGVN traded down $0.01 during mid-day trading on Monday, reaching $0.55. The stock had a trading volume of 75,911 shares, compared to its average volume of 223,505. The stock has a market cap of $11.77 million, a PE ratio of -0.52 and a beta of 0.21. Longeveron has a 1 year low of $0.49 and a 1 year high of $1.92. The company has a fifty day moving average price of $0.60 and a 200 day moving average price of $0.86.

Longeveron (NASDAQ:LGVN) last posted its earnings results on Tuesday, November 4th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.13). The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.29 million. Longeveron had a negative return on equity of 138.44% and a negative net margin of 1,485.25%. As a group, equities research analysts expect that Longeveron will post -3.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.50.

Institutional Trading of Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd purchased a new position in Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned 0.32% of Longeveron as of its most recent SEC filing. 10.01% of the stock is currently owned by institutional investors and hedge funds.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.